| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5681526 | Medicine - Programa de Formación Médica Continuada Acreditado | 2016 | 11 Pages |
Abstract
The treatment of choice for high-risk patients is allogeneic transplant, or Hypomethylating agents (azacitidine) if it can not perform the transplant. Growth factors and trasfusional support with chelation therapy are essential in patients with low-risk MDS without del (5q), the lenalidomide treatment of choice in the latter.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
F. López Cadenas, M. DÃez Campelo,